Jack Aiello | CureTalks
Jack Aiello of San Jose, California is a leading patient advocate in multiple myeloma. In January of 1995 Jack had a terrible backache. He was diagnosed with multiple myeloma through a blood test. Since that time Jack has had stem cell transplants and clinical trials that have brought him to remission, even if only for a short time. However, ultimately he had a full allogenic (donor stem cells) transplant, resulting in a long-term remission. While he has long-term side effects, Jack's spirit remains high and is very much involved with cancer advocacy organizations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society (LLS) and Myeloma Crowd, all of which provide research dollars and education programs for multiple myeloma. He also served on myeloma committees which focus on developing clinical trials, offering his patient perspective to the National Cancer Institute, SWOG Cancer Research Institute, BMT Clinical Trials Network, and Stanford’s Scientific Review Committee.
Related Talks
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell…
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma.…
UltraCAR-T Therapy – Scope & Possibilities in Multiple Myeloma Management
Ongoing clinical trials are investigating the safety and efficacy of a new type of CAR T (Chimeric antigen receptor T-cells) therapy called UltraCAR-T…
Covid-19 Vaccines – What Multiple Myeloma Patients Should Know?
Multiple myeloma patients are often immunosuppressed for months following treatments such as maintenance therapies, immunosuppressive drugs, hematopoietic cell transplant (HCT) and CAR-T therapies.…
ASH 2020 Updates: CAR T Cell Therapies in Multiple Myeloma
We kickstart the new year with a discussion on CAR T cells in myeloma treatment with a focus on the CT053, a CAR…